Wegovy vs. Zepbound

Overview

The two leading FDA-approved weight-loss injections go head to head on efficacy, pricing, side effects, and insurance coverage.

Key Differences

Clinical Trial Comparison

Wegovy (STEP-1): 14.9% mean weight loss over 68 weeks with 2.4mg dose. 86% achieved ≥5%, 69% achieved ≥10%, 32% achieved ≥20%.

Zepbound (SURMOUNT-1): 20.9% mean weight loss over 72 weeks with 15mg dose. 96% achieved ≥5%, 85% achieved ≥10%, 57% achieved ≥20%.

The ~6% difference in mean weight loss is clinically meaningful. For a 220-lb person, that’s roughly 13 extra pounds lost with Zepbound.

The Oral Wegovy Factor

Wegovy now has an oral tablet option that injectables can’t match on convenience or price. At $149–$299/mo through NovoCare, the Wegovy Pill undercuts both injectable options. If you’re deciding between Wegovy and Zepbound, consider whether the Wegovy Pill’s convenience and lower cost outweigh Zepbound’s higher efficacy data.

Side Effects

Both share common GI side effects: nausea, vomiting, diarrhea, and constipation. Rates are generally similar, though some patients report fewer GI issues with Zepbound. Both improve with slow dose titration.

How It Compares

• Semaglutide vs Tirzepatide — the broader drug class comparison
• Mounjaro vs Zepbound — same drug, different indications
• Ozempic vs Wegovy — same drug, different indications

Frequently Asked Questions

Which is more effective — Wegovy or Zepbound?

Zepbound (tirzepatide) showed ~20.9% mean weight loss in SURMOUNT-1 over 72 weeks, compared to ~14.9% for Wegovy (semaglutide) in STEP-1 over 68 weeks. While these aren’t direct head-to-head trials, the ~6% difference in mean weight loss is clinically meaningful. For a 220-pound patient, that translates to roughly 13 more pounds of average weight loss with Zepbound. The population-level outcomes are even more striking: 57% of Zepbound patients lost ≥20% body weight in SURMOUNT-1, compared to 32% on Wegovy’s STEP-1. Zepbound’s dual GLP-1/GIP mechanism appears to drive this advantage, engaging two metabolic pathways simultaneously. Wegovy’s important counter-data point is the SELECT cardiovascular outcomes trial, which showed a 20% reduction in major adverse cardiac events in obese patients with established cardiovascular disease — an outcomes benefit Zepbound doesn’t yet have in weight-loss populations. For maximum weight loss, the evidence favors Zepbound. For cardiovascular risk reduction as a co-equal goal, Wegovy has stronger data.

Which is cheaper without insurance?

Zepbound through LillyDirect starts at $299/month for the 2.5 mg starter dose, making it $50/month cheaper than injectable Wegovy at $349/month through NovoCare during the initial dosing period. At the highest maintenance doses, Zepbound rises to $449/month through LillyDirect while injectable Wegovy holds steady at $349/month, reversing the cost advantage at full therapeutic dose. However, the broader pricing picture includes a third option: the Wegovy Pill at $149–299/month through NovoCare is the cheapest brand-name semaglutide product and significantly undercuts injectable Zepbound at every price tier. If you’re primarily cost-sensitive, the decision comes down to whether the Wegovy Pill’s ~13.6% average weight loss (OASIS 4 trial) meets your goals, or whether Zepbound’s ~20.9% average weight loss (SURMOUNT-1 trial) justifies paying roughly double. For uninsured patients prioritizing maximum weight loss per dollar spent, Zepbound at $299–449/month through LillyDirect offers the strongest efficacy-to-cost ratio. Use our cost calculator to model both scenarios with your specific dose and access pathway.

Should I choose the cheaper pill instead?

The Wegovy Pill at $149/month is a compelling option for many patients, but the right choice depends on your weight-loss goals. If maximum weight loss is your priority — particularly if you have significant weight to lose and want the strongest clinical evidence — Zepbound’s ~20.9% average loss at $299/month through LillyDirect delivers 8–9 more percentage points of average weight loss for roughly double the price of the Wegovy Pill starter dose. That trade-off may be worth it. However, if you’re seeking moderate to significant weight loss with the lowest barrier to entry and no needles, the Wegovy Pill at $149/month delivering ~13.6% average weight loss is a strong clinical value. In the OASIS 4 trial, 60% of oral Wegovy patients lost ≥10% body weight — a meaningful outcome for most patients’ goals. For patients who are hesitant about injectables or have cost constraints, starting with the Wegovy Pill and escalating to injectable Zepbound later if needed is a reasonable clinical strategy to discuss with your provider.

Keep Reading

• Wegovy Pill vs Wegovy Injection — comparing Wegovy formats
• Oral vs Injectable GLP-1 — the full format comparison
• Complete GLP-1 Cost Guide — every pricing pathway compared